A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of palifermin
(recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of oral
mucositis in subjects with stage 2B and 3 locally advanced, colon cancer receiving
chemotherapy as an adjuvant treatment for their disease.